Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761088
Company: CELLTRION INC
Company: CELLTRION INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| TRUXIMA | RITUXIMAB-ABBS | 100MG/10ML(10MG/ML) | INJECTABLE;INJECTION | Prescription | None | No | No |
| TRUXIMA | RITUXIMAB-ABBS | 500MG/50ML(10MG/ML) | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 11/28/2018 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761088s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761088Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761088Orig1s000TOC.html |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 06/29/2026 | SUPPL-35 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761088s035lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761088Orig1s035ltr.pdf | |
| 06/09/2025 | SUPPL-32 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761088Orig1s032lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761088Orig1s032ltr.pdf | |
| 02/04/2022 | SUPPL-18 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761088Orig1s018ltr.pdf | |
| 05/29/2020 | SUPPL-9 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761088Orig1s009ltr.pdf | |
| 12/18/2019 | SUPPL-6 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s005, s006ltr.pdf | |
| 12/18/2019 | SUPPL-5 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s005, s006ltr.pdf | |
| 05/23/2019 | SUPPL-2 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s001s002Replacementltr.pdf | |
| 05/23/2019 | SUPPL-1 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s001s002Replacementltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 06/29/2026 | SUPPL-35 | Bioequivalence | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761088s035lbl.pdf | |
| 06/09/2025 | SUPPL-32 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761088Orig1s032lbl.pdf | |
| 02/04/2022 | SUPPL-18 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf | |
| 02/04/2022 | SUPPL-18 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf | |
| 05/29/2020 | SUPPL-9 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf | |
| 05/29/2020 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf | |
| 12/18/2019 | SUPPL-6 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf | |
| 12/18/2019 | SUPPL-5 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf | |
| 05/23/2019 | SUPPL-2 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf | |
| 05/23/2019 | SUPPL-1 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf | |
| 11/28/2018 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761088s000lbl.pdf |